1. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. (14th July 2015) Authors: Israeli, E; Goldin, E; Fishman, S; Konikoff, F; Lavy, A; Chowers, Y; Melzer, E; Lahat, A; Mahamid, M; Shirin, H; Nussinson, E; Segol, O; Ben Ya'acov, A; Shabbat, Y; Ilan, Y Journal: Clinical and experimental immunology Issue: Volume 181:Number 2(2015:Aug.) Page Start: 362 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P275 Course of COVID-19 in patients with Inflammatory Bowel Diseases treated with biologics: the Israeli experience. (27th May 2021) Authors: Lichtenstein, L; Koslowsky, B; Avni-Biron, I; Ovadia, B; Ben-Bassat, O; Naftali, T; Kopylov, U; Haberman, Y; Banai Eran, H; Eliakim, R; Lahat-Zok, A; Hirsch, A; Zittan, E; Maharshak, N; Waterman, M; Israeli, E; Goren, I; Ollech, J E; Yanai, H; Ungar, B Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S307 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗